Post ADA Diabetes Treatment Market Assessment
A Survey of Fifty Primary Care Physicians and Fifty Endocrinologists
Price $2500
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Post ADA Diabetes Treatment Market Assessment |
|
Respondent Type |
Primary Care Physicians and Endocrinologists |
|
Specialties Covered |
Primary care physicians/Internal Medicine/Endocrinology |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 30 minutes Size: 100 respondents Fielding Dates: June 18-20, 2008 |
Objectives:
To provide an overview of current type II diabetes mellitus (T2DM) treatment practices and the near-term market outlook for a set of companies and key therapeutics and the near-term market outlook for a set of companies and key therapeutic products in development by surveying practicing community-based physicians in primary care and endocrinology.
§ Determine physician perceptions and usage of Byetta® (exenatide) and Januvia™ (sitagliptin) for the treatment of type II diabetes.
§ Identify changes in diabetes treatment prescribing behavior and the drivers behind these changes.
§ Evaluate physician impressions of GLP-1 analogs and DPP-4 inhibitors that are currently in development.
§ Identify the drivers of GLP-1 and DPP4 inhibitor usage and determine the share of patients switching between the two.
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria |
§ US-based § 2 to 30 years of experience post-residency § Minimum of 75% professional time spent in clinical practice § Minimum of 80 prescriptions for T2DM written per month |
To purchase this report or request additional information, contact:
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Endocrinology |